Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | Zendy

Christopher P. Can | Zendy; Michael A. Blazing | Zendy; Robert P. Giugliano | Zendy; Amy McCagg | Zendy; Jennifer A. White | Zendy; Pierre Théroux | Zendy; Harald Darius | Zendy; Basil S. Lewis | Zendy; Ton Oude Ophuis | Zendy; J. Wouter Jukema | Zendy; Gaetano Maria De Ferrari | Zendy; Witold Rużyłło | Zendy; Paul De Lucca | Zendy; Canqing Yu | Zendy; Erin A. Bohula | Zendy; Martin Craig | Zendy; Stephen D. Wiviott | Zendy; Andrew M. Tershakovec | Zendy; MingShyan Lin | Zendy; Eugene Braunwald | Zendy; Robert M. Califf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Author(s) -

Christopher P. Can,

Michael A. Blazing,

Robert P. Giugliano,

Amy McCagg,

Jennifer A. White,

Pierre Théroux,

Harald Darius,

Basil S. Lewis,

Ton Oude Ophuis,

J. Wouter Jukema,

Gaetano Maria De Ferrari,

Witold Rużyłło,

Paul De Lucca,

Canqing Yu,

Erin A. Bohula,

Martin Craig,

Stephen D. Wiviott,

Andrew M. Tershakovec,

MingShyan Lin,

Eugene Braunwald,

Robert M. Califf

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1410489

Subject(s) - ezetimibe , statin , medicine , cholesterol , cardiology , pharmacotherapy , drug , lipoprotein , pharmacology , endocrinology

Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research